Loading...
Nexien BioPharma, Inc.
NXEN•PNK
HealthcareDrug Manufacturers - Specialty & Generic
$0.01
$0.00(0.00%)
Nexien BioPharma, Inc. (NXEN) Stock Overview
Explore Nexien BioPharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
0.00%
Profit Growth
$-425.20
↑ 33.93%
EPS Growth
$-425.20
↑ 37.93%
Operating Margin
0.00%
↑ 44.92%
ROE
9.52%
↑ 33.93%
Dividend Yield
0.00%
Analyst Recommendations data is not available for NXENAnalyst Recommendations details for NXEN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Nexien BioPharma, Inc. operates as a pharmaceutical company. It focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, and pre-clinical and clinical pathways for the treatment of various diseases, medical conditions, and disorders. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.
CEO
Mr. Richard S. Greenberg
Headquarters
4340 East Kentucky Avenue, Glendale, CO
Founded
2017